Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer

BACKGROUND: There are still no effective treatments for superficial bladder cancer (SBC)/non-muscle invasive bladder cancer. Following treatment, 20% of patients still develop metastatic disease. Superficial bladder cancer is often multifocal, has high recurrences after surgical resection and recurs...

Descripción completa

Detalles Bibliográficos
Autores principales: Simpson, G R, Horvath, A, Annels, N E, Pencavel, T, Metcalf, S, Seth, R, Peschard, P, Price, T, Coffin, R S, Mostafid, H, Melcher, A A, Harrington, K J, Pandha, H S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273343/
https://www.ncbi.nlm.nih.gov/pubmed/22240799
http://dx.doi.org/10.1038/bjc.2011.577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273343/
https://www.ncbi.nlm.nih.gov/pubmed/22240799
http://dx.doi.org/10.1038/bjc.2011.577

Ejemplares similares